DDInter1031 DDInter1261
Ledipasvir is a direct acting antiviral (DAA) medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV). HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common in the United States, and affecting 72% of all chronic HCV patients. Treatment options for chronic Hepatitis C have advanced significantly since 2011, with the development of Direct Acting Antivirals (DAAs) such as ledipasvir. More specifically, ledipasvir is an inhibitor of the Hepatitis C Virus (HCV) Non-Structural Protein 5A (NS5A), which is required for viral RNA replication and assembly of HCV virions. Although its exact mechanism of action is unknown, it is postulated to prevent hyperphosphorylation of NS5A which is required
Naloxegol, for "PEGylated naloxol" is a peripherally-selective opioid antagonist developed by AstraZeneca. It was approved by the FDA in September 2014 and is indicated for the treatment of opioid-induced constipation (OIC) in adult patients with chronic non‑cancer pain. The advantage of naloxegol over the opioid antagonist naloxone is that its PEGylated structure allows for high selectivity for peripheral opioid receptors and lack of entry into the central nervous system through the blood-brain barrier.
Naloxegol {u} may cause a minor interaction that can limit clinical effects when taken with {v} Ulipristal
Naloxegol {u} may cause a minor interaction that can limit clinical effects when taken with {v} Neratinib
Naloxegol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Griseofulvin
Naloxegol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Somapacitan
Naloxegol {u} may lead to a major life threatening interaction when taken with {v} Conivaptan
Naloxegol {u} may lead to a major life threatening interaction when taken with {v} Stiripentol
Naloxegol may cause a minor interaction that can limit clinical effects when taken with Ulipristal
Naloxegol may cause a minor interaction that can limit clinical effects when taken with Neratinib
Naloxegol may cause a moderate interaction that could exacerbate diseases when taken with Griseofulvin
Naloxegol may cause a moderate interaction that could exacerbate diseases when taken with Somapacitan
Naloxegol may lead to a major life threatening interaction when taken with Conivaptan
Naloxegol may lead to a major life threatening interaction when taken with Stiripentol